EF Petricoin

553 total citations
14 papers, 438 citations indexed

About

EF Petricoin is a scholar working on Molecular Biology, Spectroscopy and Pulmonary and Respiratory Medicine. According to data from OpenAlex, EF Petricoin has authored 14 papers receiving a total of 438 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Molecular Biology, 5 papers in Spectroscopy and 3 papers in Pulmonary and Respiratory Medicine. Recurrent topics in EF Petricoin's work include Advanced Proteomics Techniques and Applications (4 papers), Advanced Biosensing Techniques and Applications (3 papers) and Radiomics and Machine Learning in Medical Imaging (2 papers). EF Petricoin is often cited by papers focused on Advanced Proteomics Techniques and Applications (4 papers), Advanced Biosensing Techniques and Applications (3 papers) and Radiomics and Machine Learning in Medical Imaging (2 papers). EF Petricoin collaborates with scholars based in United States, Italy and Russia. EF Petricoin's co-authors include L A Liotta, Katherine M. Sheehan, Christian Gulmann, Mark S. Lowenthal, Arpita Mehta, Thomas P. Conrads, Timothy D. Veenstra, Lance A. Liotta, David A. Fishman and Valerie Calvert and has published in prestigious journals such as Journal of Clinical Oncology, JNCI Journal of the National Cancer Institute and Cancer Research.

In The Last Decade

EF Petricoin

13 papers receiving 431 citations

Peers

Countries citing papers authored by EF Petricoin

Since Specialization

Citations

This map shows the geographic impact of EF Petricoin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by EF Petricoin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites EF Petricoin more than expected).

Fields of papers citing papers by EF Petricoin

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by EF Petricoin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by EF Petricoin. The network helps show where EF Petricoin may publish in the future.

Co-authorship network of co-authors of EF Petricoin

This figure shows the co-authorship network connecting the top 25 collaborators of EF Petricoin. A scholar is included among the top collaborators of EF Petricoin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with EF Petricoin. EF Petricoin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

14 of 14 papers shown

#	Work	Indexed citations
1	Abstract OT3-02-06: Utilizing multiomic advanced diagnostics to identify CDK4/6 inhibitor response predictors and a post-treatment multiomic signature for patients with ER+/HER2- metastatic breast cancer (SIDEOUT-3) 2019 ·Cancer Research ·(unknown), Mariaelena Pierobon, Neelima Denduluri, Frances Valdes-Albini, Andres Forero‐Torres, Amy S. Clark, Rachel L. Yung, Monica Mita, (unknown), (unknown), (unknown), Robert L. Murphy, Christos Hatzis, Daniel Zelterman, Lance A. Liotta, EF Petricoin	1
2	Abstract P3-07-48: Prediction of complete pathologic response to veliparib/carboplatin plus standard neoadjuvant therapy in HER2 negative breast cancer: Exploratory protein pathway marker results from the I-SPY 2 trial 2016 ·Cancer Research ·(unknown), Christopher Yau, (unknown), (unknown), Jiapeng Deng, Lamorna Brown Swigart, Gillian L. Hirst, (unknown), H. S. Rugo, OI Olopade, (unknown), DA Berry, Laura van’t Veer, EF Petricoin	2
3	Acquisition of estrogen independence induces TOB1-related mechanisms supporting breast cancer cell proliferation 2015 ·Oncogene ·Yongwei Zhang, (unknown), (unknown), Sandra A. Jablonski, Ilya G. Serebriiskii, Rishi Surana, Valerie Calvert, Ionut Bebu, Joseph Murray, Lü Jin, Michael D. Johnson, Rebecca B. Riggins, Habtom W. Ressom, EF Petricoin, Robert Clarke, Erica A. Golemis, Louis M. Weiner	21
4	Combined PDK1 and CHK1 inhibition is required to kill glioblastoma stem-like cells in vitro and in vivo 2014 ·Cell Death and Disease ·Michele Signore, (unknown), Simona Di Martino, Daniele Runci, Mauro Biffoni, Stefano Giannetti, Liliana Morgante, Martina de Majo, EF Petricoin, Louis F. Stancato, Luigi Maria Larocca, Ruggero De Maria, Roberto Pallini, Lucia Ricci‐Vitiani	70
5	Aurora kinases in childhood acute leukemia: the promise of aurora B as therapeutic target 2012 ·Leukemia ·(unknown), C. Michel Zwaan, (unknown), Mirjam W.J. Luijendijk, Valerie Calvert, EF Petricoin, Evans We, Dirk Reinhardt, Válerie de Haas, Maj Hedtjärn, Bo R. Hansen, Troels Koch, H.N. Caron, Rob Pieters, Monique L. den Boer	69
6	295 Proteomic and Circulating Free DNA Analysis Outcome Predictors in the GALAXY TrialTM (NCT01348126): a Randomized Phase IIB/III Study of Ganetespib (STA-9090) in Combination with Docetaxel Versus Docetaxel Alone in Subjects with Stage IIIb/IV NSCLC 2012 ·European Journal of Cancer ·(unknown), EF Petricoin, Janet G. Shaw, (unknown), Vojo Vukovic, Florentina Teofilovici, (unknown), R. Rosell	1
7	Homologous control of protein signaling networks 2011 ·Journal of Theoretical Biology ·Domenico Napoletani, Michele Signore, Timothy Sauer, L. A. Liotta, EF Petricoin	1
8	Breast cancer molecular profiles and tumor response of neoadjuvant doxorubicin and paclitaxel: The I-SPY TRIAL (CALGB 150007/150012, ACRIN 6657) 2009 ·Journal of Clinical Oncology ·Laura J. Esserman, (unknown), Maggie C.U. Cheang, A. DeMichele, LA Carey, Laura van ‘t Veer, Josh Gray, EF Petricoin, Kathleen Conway, (unknown), Diane C. Berry	2
9	Phosphoproteomic profiling of pediatric B-ALL patients with MLL rearrangements 2008 ·Journal of Clinical Oncology ·Benedetta Accordi, Virginia Espina, Valentina Lissandron, Gloria Milani, Geertruy te Kronnie, L. A. Liotta, EF Petricoin, Giuseppe Basso, Enrico Garaci	1
10	Array‐based proteomics: mapping of protein circuitries for diagnostics, prognostics, and therapy guidance in cancer 2006 ·The Journal of Pathology ·Christian Gulmann, Katherine M. Sheehan, (unknown), (unknown), EF Petricoin	80
11	Importance of Communication Between Producers and Consumers of Publicly Available Experimental Data 2005 ·JNCI Journal of the National Cancer Institute ·Lance A. Liotta, Mark S. Lowenthal, Arpita Mehta, Thomas P. Conrads, Timothy D. Veenstra, David A. Fishman, EF Petricoin	67
12	Proteomic profiling identifies prognostic subsets in Rhabdomyosarcoma (RMS) 2005 ·Journal of Clinical Oncology ·(unknown), Choh Yeung, Virginia Espina, Gabriel S. Eichler, Kartik Krishnan, Maria Tsokos, (unknown), (unknown), Susanne Steinberg, EF Petricoin, L. A. Liotta	0
13	Profiling of normal human leg lymph proteins using the 2-D electrophoresis and SELDI-TOF mass spectrophotometry approach. 2004 ·PubMed ·(unknown), (unknown), (unknown), EF Petricoin, (unknown)	23
14	Cancer proteomics: from biomarker discovery to signal pathway profiling. 2001 ·PubMed ·(unknown), L A Liotta, EF Petricoin	100

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact